• 1
    Mundy GR 2002 Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584593.
  • 2
    Roodman GD 2004 Mechanisms of bone metastasis. N Engl J Med 350: 16551664.
  • 3
    Nelson WG, De Marzo AM, Isaacs WB 2003 Prostate cancer. N Engl J Med 349: 366381.
  • 4
    Chambers AF, Groom AC, MacDonald IC 2002 Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563572.
  • 5
    Kingsley LA, Fournier PG, Chirgwin JM, Guise TA 2007 Molecular biology of bone metastasis. Mol Cancer Ther 6: 26092617.
  • 6
    Clines GA, Guise TA 2008 Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10: e7.
  • 7
    Jacks T, Weinberg RA 2002 Taking the study of cancer cell survival to a new dimension. Cell 111: 923925.
  • 8
    Guise TA, Chirgwin JM 2003 Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 415 (Suppl): S32S38.
  • 9
    Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA 1999 TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197206.
  • 10
    Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR 2005 Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20: 21892199.
  • 11
    Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA 2002 Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277: 2457124578.
  • 12
    Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C 2001 From transforming growth factor-beta signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 98: 30183023.
  • 13
    Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ, Chang C 2002 Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 277: 4374943756.
  • 14
    Miyaki M, Kuroki T 2003 Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 306: 799804.
  • 15
    Ball EM, Risbridger GP 2001 Activins as regulators of branching morphogenesis. Dev Biol 238: 112.
  • 16
    Carey JL, Sasur LM, Kawakubo H, Gupta V, Christian B, Bailey PM, Maheswaran S 2004 Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth. Mol Endocrinol 18: 696707.
  • 17
    Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di Trapani D, Gebbia N, Leto G 2007 MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 27: 15191525.
  • 18
    Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G 2006 Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23: 117122.
  • 19
    Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, Hsiung CY 2006 Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res 12: 487498.
  • 20
    Kang HY, Yeh S, Fujimoto N, Chang C 1999 Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274: 85708576.
  • 21
    Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R 2005 LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436439.
  • 22
    Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, Gonzalez S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF 2005 Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11: 68236834.
  • 23
    Borre M, Nerstrom B, Overgaard J 2000 Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6: 18821890.
  • 24
    Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 28152825.
  • 25
    Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, Brenner PC, Kooner R, O'Neill GF, Turner JJ, Delprado W, Lee CS, Brown DA, Breit SN, Grygiel JJ, Horvath LG, Stricker PD, Sutherland RL, Henshall SM 2006 Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 15: 711716.
  • 26
    Zhang Z, Zhao Y, Batres Y, Lin MF, Ying SY 1997 Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 234: 362365.
  • 27
    Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF Jr , Sluss PM 1996 Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology 137: 54765483.
  • 28
    McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, Risbridger GP 1997 Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 154: 535545.
  • 29
    Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K 2004 Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab 286: E927E931.
  • 30
    Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR 2006 Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99: 392401.
  • 31
    Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A 2006 Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 281: 2993829948.
  • 32
    Nagakawa O, Akashi T, Hayakawa Y, Junicho A, Koizumi K, Fujiuchi Y, Furuya Y, Matsuda T, Fuse H, Saiki I 2004 Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol Rep 12: 837841.
  • 33
    Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B 2003 Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144: 16561663.
  • 34
    Rossi MR, Ionov Y, Bakin AV, Cowell JK 2005 Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells. Cancer Genet Cytogenet 163: 123129.
  • 35
    Wang Q, Tabatabaei S, Planz B, Lin CW, Sluss PM 1999 Identification of an activin-follistatin growth modulatory system in the human prostate: Secretion and biological activity in primary cultures of prostatic epithelial cells. J Urol 161: 13781384.
  • 36
    Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC 2002 Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143: 7483.
  • 37
    Fuller K, Bayley KE, Chambers TJ 2000 Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 268: 27.
  • 38
    Sakai R, Miwa K, Eto Y 1999 Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 25: 191196.
  • 39
    Sakai R, Fujita S, Horie T, Ohyama T, Miwa K, Maki T, Okimoto N, Nakamura T, Eto Y 2000 Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone 27: 9196.
  • 40
    Sakai R, Eto Y 2001 Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol 180: 183188.
  • 41
    Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML 2008 A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105: 70827087.
  • 42
    Hirotani H, Ohtsuka-Isoya M, Mori S, Sakai R, Eto Y, Echigo S, Shinoda H 2002 Activin A increases the bone mass of grafted bone in C3H/HeJ mice. Calcif Tissue Int 70: 330338.
  • 43
    Papakonstanti EA, Kampa M, Castanas E, Stournaras C 2003 A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 17: 870881.
  • 44
    Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D, Vitale F, Migliaccio A, Auricchio F 2003 Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 161: 547556.
  • 45
    Amorino GP, Parsons SJ 2004 Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14: 287300.
  • 46
    Ruscica M, Dozio E, Boghossian S, Bovo G, Martos Riano V, Motta M, Magni P 2006 Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 147: 14661473.
  • 47
    Nagakawa O, Ogasawara M, Fujii H, Murakami K, Murata J, Fuse H, Saiki I 1998 Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett 133: 2733.
  • 48
    Qiu Y, Robinson D, Pretlow TG, Kung HJ 1998 Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 95: 36443649.
  • 49
    Deeble PD, Murphy DJ, Parsons SJ, Cox ME 2001 Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 84718482.
  • 50
    Thomas TZ, Wang H, Niclasen P, O'Bryan MK, Evans LW, Groome NP, Pedersen J, Risbridger GP 1997 Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 82: 38513858.